Works matching IS 08909091 AND DT 2020 AND VI 34 AND IP 10
Results: 12
Emergence of HIF inhibitors in Renal Cell Carcinoma.
- Published in:
- Oncology (08909091), 2020, v. 34, n. 10, p. 445
- By:
- Publication type:
- Article
Using PARP Inhibitors in Frontline Maintenance Therapy for Ovarian Cancer.
- Published in:
- Oncology (08909091), 2020, v. 34, n. 10, p. 442, doi. 10.46883/onc.2020.3410.0442
- Publication type:
- Article
Considerations for the Management of Oncology Patients During the COVID-19 Pandemic.
- Published in:
- Oncology (08909091), 2020, v. 34, n. 10, p. 432
- By:
- Publication type:
- Article
PIPELINE DRUGS.
- Published in:
- Oncology (08909091), 2020, v. 34, n. 10, p. 430
- Publication type:
- Article
The Expanding Role of Immunotherapy: "An enormous number of promising new agents".
- Published in:
- Oncology (08909091), 2020, v. 34, n. 10, p. 427
- By:
- Publication type:
- Article
Disorders of Sex Development and Malignant Germ Cell Tumors.
- Published in:
- Oncology (08909091), 2020, v. 34, n. 10, p. 421, doi. 10.46883/onc.2020.3410.0421
- By:
- Publication type:
- Article
What Are the Biggest Technology Challenges Facing Health Care?
- Published in:
- Oncology (08909091), 2020, v. 34, n. 10, p. 419
- Publication type:
- Article
FDA Approves Pralsetinib for Treatment of Adults With Metastatic RET Fusion--Positive NSCLC.
- Published in:
- Oncology (08909091), 2020, v. 34, n. 10, p. 406, doi. 10.46883/onc.2020.3410.406
- By:
- Publication type:
- Article
Strategies to Optimize Axillary Surgery in Patients With Breast Cancer Receiving Neoadjuvant Endocrine Therapy.
- Published in:
- Oncology (08909091), 2020, v. 34, n. 10, p. 397, doi. 10.46883/onc.2020.3410.0397
- By:
- Publication type:
- Article
The FDA Is Needed Now More Than Ever.
- Published in:
- Oncology (08909091), 2020, v. 34, n. 10, p. 396, doi. 10.46883/onc.2020.3410.0396
- By:
- Publication type:
- Article
Keeping Cancer in "Check".
- Published in:
- Oncology (08909091), 2020, v. 34, n. 10, p. 395
- By:
- Publication type:
- Article
Barriers to Clinical Trial Enrollment in Patients With Pancreatic Adenocarcinoma Eligible for Early-Phase Clinical Trials.
- Published in:
- Oncology (08909091), 2020, v. 34, n. 10, p. 407, doi. 10.46883/onc.2020.3410.0407
- By:
- Publication type:
- Article